Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2012

View Archived Issues

Osteros Biomedica prepares for proof-of-concept MBC-11 study

Multiple studies confirm D-type cyclins as therapeutic targets in cancer

Adaptimmune presents gene-engineered autologous T cells for multiple myeloma

Immunomedics develops antibodies with potential in the therapeutic intervention of lymphoma

Gilead Sciences patents novel sodium channel blockers

French and U.S. researchers present novel Mdm2 inhibitors for cancer

Janssen submits NDA for canagliflozin/metformin combination

4SC reports interim data from phase I/II trial of resminostat

Milestone reached in DuoBody platform collaboration

Method devised to detect biomarker of idiopathic pulmonary fibrosis

Lamazym advances to phase III alpha-mannosidosis trial

FDA approves supplemental NDA for Rescula

Kyowa Hakko Kirin begins pivotal phase III mogamulizumab study in CTCL

BrainStorm Cell Therapeutics receives grant from Israel's Office of the Chief Scientist

Amgen set to acquire deCODE Genetics

FDA accepts for review NDA for vortioxetine

NIH-sponsored trial of AstraZeneca's TB candidate commences in South Africa

Safety of antimalarial tafenoquine evaluated in phase I study

Japanese scientists present novel agents for Fabry's disease

Matrivax Research & Development Corp. patents new pneumococcal vaccines

New orexin receptor antagonists prepared by Taisho Pharmaceutical

Bayer submits MAA to EMA for prostate cancer treatment

U.S. researchers synthesize novel autophagy inhibitors

AstraZeneca reports on OSKIRA-4 phase IIb fostamatinib study

ISIS-TTRRx receives fast track designation from FDA

Insero Health completes phase Ib study of INS-001

FDA accepts for review macitentan NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...